TGFB1 and systemic sclerosis: The enhancement of cellular SIRT3 by hexafluorine treatment blocked intracellular TGF-β signalling and fibrotic responses and attenuated the activation phenotype of systemic sclerosis fibroblasts, while the accumulation of mitochondrial and cytoplasmic ROS in fibroblasts was reduced (142, 143).